Frontiers3h
Understanding Adverse Effect in Myeloma Patients treated with T Cell Redirecting Immunotherapies
Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...
Joplin Globe14h
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis ...
Mapping study provides new insights into cell types and interactions in multiple sclerosis
An international team of researchers led by Professor Dr. Lucas Schirmer and Professor Dr. Julio Saez-Rodriguez from the ...
Multiple Sclerosis News Today2d
Study IDs 2 enzymes that mediate toxic effects of saturated fats in MS
Two enzymes in brain cells are responsible for mediating the toxic effects of certain fat molecules in multiple sclerosis, ...
Optimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCa
Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Immunic (IMUX – Research Report) on November 7 and set a price target ...
Cancer Research6d
About the Journal
Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to ...